RYTMRhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals (NASDAQ:RYTM) is expanding commercialization of its rare-disease obesity treatment IMCIVREE while advancing additional melanocortin-4 receptor, or MC4R, agonists through development, Chief Financial Officer Hunter Smith said during a Canaccord Genuity fireside chat. Smith sai

IMCIVREE revenue surged 19% sequentially as HO patient adoption accelerated post-approval.

Moby summary of Rhythm Pharmaceuticals, Inc.'s Q2 2026 earnings call

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company cited an early positive reception to its U.S. launch in acquired hypothalamic obesity, or HO. Chief E

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +9.88% and +6.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

In early August 2026, Rhythm Pharmaceuticals is scheduled to report quarterly results that analysts expect will show higher revenue but a year-over-year earnings decline, with many anticipating a potential earnings beat versus consensus estimates. This combination of rising sales and the prospect of outperforming forecasts, despite weaker earnings, has drawn fresh attention to how Rhythm’s growth profile and cost base are evolving. We’ll now examine how anticipation of an earnings beat,...

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street analysts are reshuffling their bets ahead of the busiest earnings week of the quarter, and the moves span everything from legacy automakers to crypto miners to space launch companies. Find out which names just got upgraded, downgraded, or picked up for the first time.